Transparency notifications BlackRock, Inc.

Brussels (Belgium), 8 November 2019 – 20:00 (CET) – regulated information

1.  Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 5 and 6 November 2019 respectively.
In the first notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has decreased and has crossed downwards the 5% threshold on 4 November 2019. 

On 4 November 2019, BlackRock, Inc. (taking into account the holding of its affiliates) Inc. owned 9 677 390 UCB shares with voting rights (versus 9 841 224 in its previous notification), representing 4.98% of the total number of shares issued by the company (194 505 658) (versus 5.06% in its previous notification), as well as 225 581 equivalent financial instruments (versus 481 019 in its previous notification) representing 0.12% of the total number of shares issued by the company (versus 0.25% in its previous notification). 
In the second notification, BlackRock, Inc., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has increased and has crossed the 5% threshold on 5 November 2019. 

On 5 November 2019, BlackRock, Inc. (taking into account the holding of its affiliates) 9 753 879 UCB shares with voting rights, representing 5.01% of the total number of shares issued by the company, as well as 216 713 equivalent financial instruments, representing 0.11% of the total number of shares issued by the company.

2.  Further information

This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news